The angiotensin receptor blocker, azilsartan medoxomil (TAK-491), suppresses vascular wall expression of plasminogen activator inhibitor type-I protein potentially facilitating the stabilization of atherosclerotic plaques

Journal of Cardiovascular Pharmacology

Volumn 58, Issue 2, 2011, Pages 143-148

  French, Christopher J ^a   Zaman, A K M Tarikuz ^a   Sobel, Burton E ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

angiotensin receptor blockers (ARBs); atherosclerosis; PAI 1; plaque

Indexed keywords

AZILSARTAN MEDOXOMIL; COLLAGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL WALL; CELL ASSAY; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LIPID DIET; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; AORTA; APOLIPOPROTEINS E; BENZIMIDAZOLES; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, KNOCKOUT; OXADIAZOLES; PLAQUE, ATHEROSCLEROTIC; PLASMINOGEN ACTIVATOR INHIBITOR 1; RENIN;

EID: 80051801296     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31821dcbea     Document Type: Article

References (32)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics- 2010 update: A report from the American Heart Association. Circulation. 2010;121:e46-e215.
2. Davies MJ, Bland JM, Hangartner JR, et al. Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischaemic death. Eur Heart J. 1989;10:203-208.
3. Falk E. Unstable angina with fatal outcome: Dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation. 1985;71:699-708.
4. Falk E. Morphologic features of unstable atherothrombotic plaques underlying acute coronary syndromes. Am J Cardiol. 1989;63:114E-120E.
5. Benditt EP, Benditt JM. Evidence for a monoclonal origin of human atherosclerotic plaques. Proc Natl Acad Sci U S A. 1973;70:1753-1756.
6. Davies MJ, Richardson PD, Woolf N, et al. Risk of thrombosis in human atherosclerotic plaques: Role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J. 1993;69:377-381.
7. Davies MJ, Woolf N, Rowles P, et al. Lipid and cellular constituents of unstable human aortic plaques. Basic Res Cardiol. 1994;89(suppl 1):33-39.
8. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995; 92:657-671.
9. Lendon CL, Davies MJ, Born GV, et al. Atherosclerotic plaque caps are locally weakened when macrophages density is increased. Atherosclerosis. 1991;87:87-90.
10. Loree HM, Kamm RD, Stringfellow RG, et al. Effects of fibrous cap thickness on peak circumferential stress in model atherosclerotic vessels. Circ Res. 1992;71:850-858.
11. Murry CE, Gipaya CT, Bartosek T, et al. Monoclonality of smooth muscle cells in human atherosclerosis. Am J Pathol. 1997;151:697-705.
12. Richardson PD, Davies MJ, Born GV. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet. 1989;2:941-944.
13. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91:2844-2850.
14. Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet. 1987;2: 3-9.
15. Sobel BE. Increased plasminogen activator inhibitor-1 and vasculopathy. A reconcilable paradox. Circulation. 1999;99:2496-2498.
16. Carmeliet P, Moons L, Lijnen R, et al. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: A gene targeting and gene transfer study in mice. Circulation. 1997;96: 3180-3191.
17. Schneider DJ, Hayes M, Wadsworth M, et al. Attenuation of neointimal vascular smooth muscle cellularity in atheroma by plasminogen activator inhibitor type 1 (PAI-1). J Histochem Cytochem. 2004;52:1091-1099.
18. Sobel BE, Taatjes DJ, Schneider DJ. Intramural plasminogen activator inhibitor type-1 and coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23:1979-1989.
19. Fukuda D, Enomoto S, Nagai R, et al. Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. Biomed Pharmacother. 2009;63:754-761.
20. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest. 1995;95:995-1001.
21. Ridker PM, Gaboury CL, Conlin PR, et al. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation. 1993;87:1969-1973.
22. Feener EP, Northrup JM, Aiello LP, et al. Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest. 1995;95:1353-1362.
23. Skurk T, Lee YM, Hauner H. Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture. Hypertension. 2001;37:1336-1340.
24. Rincon M, Enslen H, Raingeaud J, et al. Interferon-gamma expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway. EMBO J. 1998;17:2817-2829.
25. Caudill SP. Characterizing populations of individuals using pooled samples. J Expo Sci Environ Epidemiol. 2008;20:29-37.
26. Ojima M, Igata H, Tanaka M, et al. In vitro antagonistic properties of a new Angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exper Ther. 2010;336:801-808.
27. Sobel BE, Schneider DJ, Lee YH, et al. Insulin resistance increases PAI-1 in the heart. Biochem Biophys Res Commun. 2006;346:102-107.
28. Goodfield NE, Newby DE, Ludlam CA, et al. Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation. 1999;99:2983-2985.
29. Koh KK, Chung WJ, Ahn JY, et al. Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: A randomized, double-blind, placebocontrolled study. Atherosclerosis. 2004;177:155-160.
30. Erdem Y, Usalan C,Haznedaroglu IC, et al. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am J Hypertens. 1999;12(pt 1):1071-1076.
31. Weber M. Antihypertensive efficacy of the new angiotensin receptor blocker Azilsartan medoxomil in combination with amlodipine. J Clin Hypertens. 2010;12(suppl 1):A115.
32. White W. The new angiotensin Azilsartan medoxomil has superior 24-hour blood pressure lowering efficacy to both olmesartan and valsartan. J Clin Hypertens. 2010;12(suppl 1):A116.